TrialSafety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Trial details
- Registry ID
- NCT05652907
- Phase
- Phase 2
QNTM
Quantum Biopharma
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)NCT05652907 | Quantum Biopharma | Phase 2 | Terminated | 2023-05-24Actual |
Latest recorded trial changes
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
NCT05652907 · Quantum Biopharma
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity
+ After
Measure: Targeted Treatment Effect of 30% Decrease From Baseline to Day 28 in the Average Daily Pain Intensity